GoAI
Get started
BrainsWay Ltd. logo

BrainsWay Ltd.

BWAY

NASDAQHealthcareMedical - Specialties

Open in GoAI

Regular session

$14.34

−$0.40 · -2.71%

Aug 24, 12:28 PM ET

BWAY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

73

Undervalued

Momentum

53

Neutral

Sentiment

60

Mixed

Risk resilience

62

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

Industry
Medical - Specialties
Sector
Healthcare
Headquarters
IL
CEO
Hadar Levy
Listed since
Apr 17, 2019
Employees
129

Market position

Day range

Current $14.34

52-week range

Current $14.34

Open
$14.52
Previous close
$14.74
Volume
45.44K
0.35× average
Average volume
130.47K
Average daily volume
Market cap
562.46M USD
Beta
0.15
Market reference 1
50-day average
$15.2124
-5.73% below average
200-day average
$12.9431
+10.79% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
120.58M USD
P/E (TTM)
59.01×
P/B (TTM)
7.29×
P/S (TTM)
8.85×
EV / EBITDA
10.52×
Earnings yield
4.21%
Free cash flow yield
9.04%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
75.33%
Operating margin
12.18%
Net margin
14.61%
Return on equity
10.42%
Return on assets
6.76%
Return on invested capital
4.66%

Financial health

Debt / equity
0.09×
Current ratio
3.83×
Altman Z-score
8.49
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends90%40%-11%-62%Gross margin, FY2021: 77.75%Gross margin, FY2022: 73.77%Gross margin, FY2023: 73.86%Gross margin, FY2024: 74.56%Gross margin, FY2025: 75.42%Operating margin, FY2021: -16.86%Operating margin, FY2022: -46.67%Operating margin, FY2023: -15.60%Operating margin, FY2024: 3.39%Operating margin, FY2025: 8.28%Net margin, FY2021: -21.79%Net margin, FY2022: -49.12%Net margin, FY2023: -13.20%Net margin, FY2024: 7.12%Net margin, FY2025: 14.62%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 77.75%. Gross margin FY2022 73.77%. Gross margin FY2023 73.86%. Gross margin FY2024 74.56%. Gross margin FY2025 75.42%. Operating margin FY2021 -16.86%. Operating margin FY2022 -46.67%. Operating margin FY2023 -15.60%. Operating margin FY2024 3.39%. Operating margin FY2025 8.28%. Net margin FY2021 -21.79%. Net margin FY2022 -49.12%. Net margin FY2023 -13.20%. Net margin FY2024 7.12%. Net margin FY2025 14.62%.

Income trends

Revenue

52.23M USD+27.33%

Operating income

4.32M USD+210.78%

Net income

7.63M USD+161.31%
Income trends across reported periods58.78M USD32.55M USD6.32M USD−19.91M USDRevenue, FY2021: 29.66M USDRevenue, FY2022: 27.18M USDRevenue, FY2023: 31.79M USDRevenue, FY2024: 41.02M USDRevenue, FY2025: 52.23M USDOperating income, FY2021: −5M USDOperating income, FY2022: −12.68M USDOperating income, FY2023: −4.96M USDOperating income, FY2024: 1.39M USDOperating income, FY2025: 4.32M USDNet income, FY2021: −6.46M USDNet income, FY2022: −13.35M USDNet income, FY2023: −4.2M USDNet income, FY2024: 2.92M USDNet income, FY2025: 7.63M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 29.66M USD. Revenue FY2022 27.18M USD. Revenue FY2023 31.79M USD. Revenue FY2024 41.02M USD. Revenue FY2025 52.23M USD. Operating income FY2021 −5M USD. Operating income FY2022 −12.68M USD. Operating income FY2023 −4.96M USD. Operating income FY2024 1.39M USD. Operating income FY2025 4.32M USD. Net income FY2021 −6.46M USD. Net income FY2022 −13.35M USD. Net income FY2023 −4.2M USD. Net income FY2024 2.92M USD. Net income FY2025 7.63M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue52.23M USD41.02M USD31.79M USD27.18M USD29.66M USD
Cost of goods sold12.84M USD10.44M USD8.31M USD7.13M USD6.6M USD
Gross profit39.39M USD30.58M USD23.48M USD20.05M USD23.06M USD
Research and development9.6M USD7.19M USD6.67M USD7.68M USD6.39M USD
Selling, general, and administrative25.46M USD22M USD21.64M USD25.05M USD21.66M USD
Operating expenses35.06M USD29.19M USD28.44M USD32.73M USD28.06M USD
Interest income5.64M USD2.48M USD2.17M USD1.11M USD225K USD
Interest expense2.23M USD1.36M USD298K USD68K USD141K USD
Depreciation and amortization1.54M USD1.77M USD1.34M USD1.53M USD1.69M USD
Operating income4.32M USD1.39M USD−4.96M USD−12.68M USD−5M USD
Net income7.63M USD2.92M USD−4.2M USD−13.35M USD−6.46M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
91%
10 beats, 1 miss, 0 met estimates
Average EPS surprise
+246.11%
11 comparable reports
Latest EPS result
0.14
Estimate 0.1 · Beat by 40.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.180.120.070.01Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 0.04, estimate 0.03, surprise +33.33%, Beat. Q2 2025, reported May 13, 2025: actual 0.02, estimate 0.01, surprise +100.00%, Beat. Q3 2025, reported Aug 13, 2025: actual 0.05, estimate 0.04, surprise +25.00%, Beat. Q4 2025, reported Nov 11, 2025: actual 0.04, estimate 0.05, surprise -20.00%, Miss. Q1 2026, reported Mar 11, 2026: actual 0.14, estimate 0.06, surprise +133.33%, Beat. Q2 2026, reported May 13, 2026: actual 0.12, estimate 0.05, surprise +140.00%, Beat. Q3 2026, reported Aug 12, 2026: actual 0.14, estimate 0.1, surprise +40.00%, Beat. Q4 2026, reported Nov 10, 2026: actual —, estimate 0.09, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates18.35M15.62M12.9M10.17MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 11.41M USD, estimate 10.88M USD, surprise +4.96%, Beat. Q2 2025, reported May 13, 2025: actual 11.54M USD, estimate 11.45M USD, surprise +0.77%, Beat. Q3 2025, reported Aug 13, 2025: actual 12.63M USD, estimate 12.34M USD, surprise +2.41%, Beat. Q4 2025, reported Nov 11, 2025: actual 13.51M USD, estimate 13.03M USD, surprise +3.67%, Beat. Q1 2026, reported Mar 11, 2026: actual 14.55M USD, estimate 14.02M USD, surprise +3.77%, Beat. Q2 2026, reported May 13, 2026: actual 15.53M USD, estimate 14.63M USD, surprise +6.13%, Beat. Q3 2026, reported Aug 12, 2026: actual 17.11M USD, estimate 16.54M USD, surprise +3.42%, Beat. Q4 2026, reported Nov 10, 2026: actual —, estimate 17.65M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$17.00

18.55% upside
Past 12 months12-month forecastHigh $20.00Average $17.00Low $14.00

Rating distribution

8 ratings
Strong buy00%
Buy788%
Hold113%
Sell00%
Strong sell00%

BWAY news

zacks.com

Brainsway (BWAY) Upgraded to Buy: Here's Why

Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read source
defenseworld.net

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives $16.95 Average Target Price from Brokerages

Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, Marketbeat Ratings reports. One research…

Read source
marketbeat.com

Brainsway Q2 Earnings Call Highlights

Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT…

Read source
seekingalpha.com

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025

Read source
seekingalpha.com

BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem

BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026 revenue up 35% YoY,…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 4, 2026

2:1

BWAY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$441.01

+0.38%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.17

+0.03%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.77

-0.05%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.6

-0.58%

Sanofi logo

SNY

Sanofi

$45.602

-0.54%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.38

-1.04%

ETFs holding BWAY

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Israel Innovative Technology ETF logoARK Israel Innovative Technology ETFIZRL
Market value
2.16M
Weight
1.62%
AUM
136.9M USD
Expense ratio
0.49%
Price / 1D
$28.75-1.00%
Amplify BlueStar Israel Technology ETF logoAmplify BlueStar Israel Technology ETFITEQ
Market value
1.1M
Weight
0.97%
AUM
113.42M USD
Expense ratio
0.75%
Price / 1D
$62.025-1.85%
ActivePassive International Equity ETF logoActivePassive International Equity ETFAPIE
Market value
253.31K
Weight
0.02%
AUM
953.79M USD
Expense ratio
0.45%
Price / 1D
$39.49-0.69%
Even Herd Long Short ETF logoEven Herd Long Short ETFEHLS
Market value
224.4K
Weight
0.39%
AUM
59.5M USD
Expense ratio
2.62%
Price / 1D
$25.39-0.53%
iShares Neuroscience and Healthcare ETF logoiShares Neuroscience and Healthcare ETFIBRN
Market value
33.87K
Weight
0.43%
AUM
7.92M USD
Expense ratio
0.47%
Price / 1D
$39.45-0.50%
Defiance Autism Impact ETF logoDefiance Autism Impact ETFASD
Market value
33.17K
Weight
2.35%
AUM
1.41M USD
Expense ratio
0.79%
Price / 1D
$28.17-0.32%

Continue in GoAI

Research BWAY

research.disclaimer